Literature DB >> 8387089

Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications.

.   

Abstract

OBJECTIVE: To determine the prevalence of hypertension in newly diagnosed type 2 diabetic patients and its association with risk factors for cardiovascular and diabetic complications.
DESIGN: Cross-sectional study. PATIENTS: Newly diagnosed type 2 diabetic patients (n = 3648, mean age 52 years, 59% male) recruited for the UK Prospective Diabetes Study (UKPDS). MEASUREMENTS: Blood pressure, body mass index, waist:hip ratio, ECG signs of ischaemia and of left ventricular hypertrophy (Minnesota code), fasting plasma glucose, urate, creatinine, insulin, triglycerides, high-density lipoprotein-, low-density lipoprotein- and total cholesterol, urinary albumin:creatinine ratio, retinopathy grading.
RESULTS: Thirty-nine per cent of the patients (35% of the males, 46% of the females) were hypertensive (mean blood pressure > or = 160 systolic and/or > or = 90 mmHg diastolic 2 and 9 months after diagnosis of diabetes, or taking antihypertensive therapy). The hypertensive patients had a greater mean body mass index (30.1 versus 28.0 kg/m2, P < 0.0001) than the normotensive patients. They also had higher fasting plasma triglyceride (1.94 versus 1.69 mmol/l, P < 0.0001) and insulin (15.0 versus 12.8 mU/l, P < 0.0001) levels but these associations disappeared or weakened when obesity was taken into account. Hypertensive compared with normotensive subjects suffered a higher prevalence of cardiovascular events before the diagnosis of diabetes (4.8 versus 2.5%, P < 0.0001), of microalbuminuria (albumin:creatinine ratio > 5.0 g/mol; 24 versus 14%, P < 0.0001), of ECG signs of probable and possible ischaemia (24 versus 14%, P < 0.0001) and of left ventricular hypertrophy (8.5 versus 3.8%; P < 0.0001). The prevalence of retinopathy was similar in the two groups.
CONCLUSIONS: Hypertension is common in newly diagnosed type 2 diabetes and is associated with obesity. The association between hypertension and higher triglyceride and insulin levels may be secondary to obesity in this population. An association between hypertension and cardiovascular complications is already apparent at diagnosis of diabetes.

Entities:  

Mesh:

Year:  1993        PMID: 8387089     DOI: 10.1097/00004872-199303000-00012

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  105 in total

Review 1.  The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes.

Authors:  P King; I Peacock; R Donnelly
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

Review 2.  Beta-blockers in the management of hypertension in patients with type 2 diabetes mellitus: is there a role?

Authors:  F Dunne; M J Kendall; U Martin
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  Management of diabetic nephropathy.

Authors:  L Foggensteiner; S Mulroy; J Firth
Journal:  J R Soc Med       Date:  2001-05       Impact factor: 5.344

4.  Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study.

Authors:  A I Adler; I M Stratton; H A Neil; J S Yudkin; D R Matthews; C A Cull; A D Wright; R C Turner; R R Holman
Journal:  BMJ       Date:  2000-08-12

Review 5.  What should we measure in the diabetic patient and how does this respond to therapy?

Authors:  Desmond G Johnston; Stephen Robinson; Shareen Forbes
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

Review 6.  Pathogenesis of hypertension in diabetes.

Authors:  Sameer N Stas; Fadi A El-Atat; James R Sowers
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

Review 7.  Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Wei-Xin Li; Jian-Feng Gou; Jin-Hui Tian; Xiang Yan; Lin Yang
Journal:  Curr Ther Res Clin Exp       Date:  2010-08

Review 8.  Metabolic safety of antihypertensive drugs: myth versus reality.

Authors:  Sameer Stas; Lama Appesh; James Sowers
Journal:  Curr Hypertens Rep       Date:  2006-10       Impact factor: 5.369

Review 9.  The use of ACE inhibitors on diabetic patients without renal disease.

Authors:  Dmitri Kirpichnikov; Nathaniel Winer; James R Sowers
Journal:  Curr Diab Rep       Date:  2002-02       Impact factor: 4.810

Review 10.  Treatment of hypertension in diabetic patients with nephropathy.

Authors:  R Komers; S Anderson
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.